Addex (ADXN) Q3 2025 earnings review
Cash Runway Extended, but Clinical Progress Remains Unfunded
Addex Therapeutics reported a net loss of CHF 1.6 million, with the P&L now heavily impacted by its share of losses (CHF 0.9 million) from the Neurosterix spin-out. The company has successfully reduced its operational cash burn, ending the quarter with CHF 2.2 million in cash and a stated runway through mid-2026. However, this runway is for minimal operations only. Management has been clear that current funds are insufficient to advance its key unpartnered assets—GABAB PAM for chronic cough and dipraglurant for post-stroke recovery—into clinical trials. The company's entire strategy and future value now hinge on securing new financing or partnerships.
🐂 Bull Case
The collaboration with Indivior, which has selected a GABAB PAM candidate for development, and the successful $65M financing of the Neurosterix spin-out validate the potential of Addex's allosteric modulator platform.
The 20% equity stake in the well-funded Neurosterix provides significant, non-dilutive upside potential if its M4 PAM program for schizophrenia or other assets succeed.
🐻 Bear Case
The company's own filings note a "material uncertainty" about its ability to continue as a going concern. It lacks the capital to fund the clinical trials necessary to create value from its promising unpartnered assets.
The share of losses from the 20%-owned Neurosterix has become the largest component of Addex's net loss, creating a significant non-cash drag on reported earnings.
⚖️ Verdict: 🔴
Bearish. The company is in survival mode. While the reduced cash burn extends the operational runway, this is a misleading metric as it does not fund any value-creating clinical advancement. The entire investment case rests on future, unsecured financing or partnership events, making the risk profile extremely high.
Key Themes
Clinical Development is Unfunded
This is the company's central challenge. Management has explicitly stated on calls and the financials include a "going concern" warning, clarifying that the current cash of CHF 2.2 million is insufficient to progress its unpartnered programs (GABAB PAM for cough, dipraglurant) into the clinic. All pipeline advancement is contingent on raising new capital or signing partnership deals.
Contradiction: 'Successful' Spin-Out Drags Down P&L
While the Neurosterix spin-out was framed as a strategic success that provided non-dilutive funding, the data shows a significant negative consequence. Addex's share of Neurosterix's net loss was CHF 0.9 million this quarter, exceeding its own operating loss of CHF 0.7 million. This non-cash charge is now the primary driver of Addex's reported net loss, contradicting the purely positive narrative.
GABAB PAM Platform Shows Promise
The GABAB PAM platform is Addex's core scientific asset and is advancing on two fronts. The partnership with Indivior has yielded a development candidate for substance use disorder, validating the technology. Separately, Addex's wholly-owned candidate for chronic cough has shown robust preclinical data, with a reported 70% cough reduction and a >60x safety margin, positioning it as a potentially best-in-class asset if it can be funded.
Value from Neurosterix Equity Stake
Despite the accounting losses, the 20% equity stake in Neurosterix represents a key long-term value driver. Neurosterix is well-capitalized with $65 million and is advancing multiple programs, including an M4 PAM candidate expected to dose patients in 2025. Positive clinical data from Neurosterix could significantly increase the value of Addex's holding.
High Dependence on External Parties
A significant portion of Addex's potential value is tied to the clinical and commercial success of its partners and associates, namely Indivior and Neurosterix. Addex has limited to no operational control over these programs, making it reliant on the execution of third parties.
Strategic Shift to Capital-Light Model
The Neurosterix spin-out and focus on partnerships (Indivior, Stalicla investment) demonstrate a clear strategic pivot. The company is operating as a lean holding company, aiming to de-risk assets to a stage where they can attract external funding, thereby preserving its own limited capital for basic operations.
Other KPIs
Reversing. The meaningful revenue stream from the Indivior research collaboration, which was CHF 309k in the first nine months of 2024, ended in mid-2024. Current 'revenue' is negligible and relates only to the reinvoicing of patent maintenance costs. The company has no significant recurring income.
This is a new, material line item resulting from the 20% equity stake in the Neurosterix spin-out, which began operations in Q2 2024. The loss appears to be stabilizing at approximately CHF 0.8-0.9 million per quarter and is now the single largest contributor to Addex's consolidated net loss.
Guidance
Stable. The company maintains its guidance for its cash runway. However, it's critical to note this guidance only covers minimal corporate and operational expenses and does not include funding for planned clinical trials for its unpartnered assets.
Key Questions
Quantifying the Funding Gap
Regarding the cash runway to mid-2026, what is the estimated cash required to complete IND-enabling studies and a Phase 1 trial for the GABAB PAM chronic cough program?
Neurosterix Value vs. P&L Drag
The share of loss from Neurosterix is now larger than Addex's own operating loss. How should investors weigh the potential future value of this 20% stake against the ongoing negative impact on reported earnings?
Indivior Milestone Timeline
What are the next key development steps for the Indivior-partnered GABAB PAM program, and what is the potential timing for the next milestone payment?
Partnering Priorities
Of your unpartnered assets—dipraglurant, the GABAB cough program, and the returned ADX71149—which is the highest priority for partnering, and can you characterize the nature of the ongoing discussions?